HOOKIPA Pharma Inc. — fact timeline

Julie O'Neill was appointed as non-executive chair at HOOKIPA Pharma Inc..

“the Company’s board of directors (the “Board”) appointed Julie O’Neill to serve as non-executive chair of the Board, effective as of the Effective Time.”

Timothy Reilly resigned as director at HOOKIPA Pharma Inc..

“On August 27, 2024, Timothy Reilly, Ph.D., notified the Company of his resignation as a director of the Company, effective as of the Effective Time.”

Jan van de Winkel resigned as director at HOOKIPA Pharma Inc..

“On August 27, 2024, Jan van de Winkel, Ph.D., notified HOOKIPA Pharma Inc. (the “Company”) of his resignation as a director of the Company, effective as of August 30, 2024 at 12:00 p.m. Eastern Time”

Malte Peters was appointed as Chief Executive Officer and President at HOOKIPA Pharma Inc..

“the Company’s board of directors (the “Board”) appointed Malte Peters, M.D., as the Company’s Chief Executive Officer and President, effective July 22, 2024.”

Reinhard Kandera resigned as Director at HOOKIPA Pharma Inc..

“Mr. Kandera also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Financial Officer”

Reinhard Kandera departed as Chief Financial Officer at HOOKIPA Pharma Inc..

“On July 22, 2024, Reinhard Kandera separated as the Chief Financial Officer of the Company.”

Joern Aldag resigned as Director at HOOKIPA Pharma Inc..

“Mr. Aldag also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Executive Officer”

Joern Aldag departed as Chief Executive Officer at HOOKIPA Pharma Inc..

“On July 22, 2024, Joern Aldag separated as the Chief Executive Officer of HOOKIPA Pharma Inc. (the “Company”).”

HOOKIPA Pharma Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million.

“Revenue was $36.6 million for the three months ended March 31, 2024, compared to $3.2 million for the same period in 2023.”

HOOKIPA Pharma Inc. reported financial results for the fourth quarter and full year 2023.

“On March 22, 2024, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2023.”

HOOKIPA Pharma Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“from The Nasdaq Global Select Market tier to The Nasdaq Capital Market tier, as well as the Company’s request for a second 180-calendar day period, or until July 29, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the Company’s Common Stock from The Nasdaq Global Select Market to The Nasdaq”

HOOKIPA Pharma Inc. announced a impairment with charges of between $10 million and $13 million affecting GMP facility project.

“HOOKIPA expects a non-cash impairment of “assets under construction” between $10 million and $13 million from the discontinuation of the GMP facility project as part of the Reduction Plan.”

HOOKIPA Pharma Inc. announced a restructuring with charges of approximately $1.5 million in severance, restructuring and related costs affecting the Company (55 full-time employees, or approximately 30% of the Company's then-current employee base).

“into an effective separation agreement, which includes a general release of claims against the Company. The workforce reduction is expected to result in approximately $1.5 million in severance, restructuring and related costs. HOOKIPA expects a non-cash impairment of “assets under construction” between $10 million and $13 million from the discontinuation”

HOOKIPA Pharma Inc. terminated Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (effective 2024-01-25).

“On January 25, 2024, HOOKIPA Pharma Inc. (“HOOKIPA”) received written notice (the “Notice”) from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively referred to as “Roche”) of their decision to terminate the Research Collaboration and License Agreement (the “Collaboration Agreement”) among Roche and Hookipa Biotech GmbH (“HOOKIPA GmbH,” and together with HOOKIPA, the “Company”), a wholly-owned subsidiary of HOOKIPA, dated October 18, 2022.”

HOOKIPA Pharma Inc. amended Amended and Restated Stock Purchase Agreement with Gilead Sciences, Inc. valued at approximately $21.25 million (effective 2023-12-20).

“On December 20, 2023, (the “Effective Date”), HOOKIPA Pharma Inc. (the “Company”) entered into an Amended and Restated Stock Purchase Agreement (the “A&R Stock Purchase Agreement”) with Gilead Sciences, Inc. (“Gilead”), which amends and restates in its entirety the Company’s Stock Purchase Agreement, dated February 15, 2022, with Gilead, pursuant to which Gilead had purchased $5.0 million of the Company’s Common Stock and committed to purchase an additional $30.0 million.”

Dr. Roman Necina changed role as Chief Operations Officer at HOOKIPA Pharma Inc..

“changed the title of the Company’s current Chief Development Officer, Dr. Roman Necina, to Chief Operations Officer, effective January 1, 2024.”

HOOKIPA Pharma Inc. reported third quarter of 2023 results: revenue $6.9 million, net income $19.1 million.

“The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023. ​ Revenue: Revenue was $6.9 million for the three months ended September 30, 2023 and $2.2 million for the three months ended September 30, 2022. This increase was primarily due to higher partial recognition of the”

Christine Baker resigned as Chief Operating Officer at HOOKIPA Pharma Inc..

“On October 20, 2023, HOOKIPA Pharma Inc. (the “Company”) announced that Christine Baker, the Company’s Chief Operating Officer, resigned on October 16, 2023 and will be leaving the Company on January 15, 2024, following a garden leave period commencing on November 1, 2023.”

HOOKIPA Pharma Inc. reported second quarter of 2023 results: revenue $2.7 million.

“The increase was primarily attributable to funds resulting from the follow-on financing in June 2023, partly offset by cash used in operating activities. ​ Revenue: Revenue was $2.7 million for the three months ended June 30, 2023 and for the three months ended June 30, 2022. A decrease of cost reimbursements received under the Restated Gilead Collaboration”

HOOKIPA Pharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“PA Pharma Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the s”

HOOKIPA Pharma Inc. shareholders approved Ratification of appointment of PwC Wirtschaftsprüfung GmbH as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-09 meeting.

“The votes cast at the Annual Meeting were as follows: For Against Abstain 35,649,440 571,982 510,711”

HOOKIPA Pharma Inc. shareholders approved Election of Class I directors: Joern Aldag, Jan Van de Winkel and David Kaufman at the 2023-06-09 meeting.

“The Company’s stockholders voted for the Class I directors as follows: Class I Director Nominee For Withhold Broker Non- Votes Joern Aldag 23,467,198 694,812 12,570,123 Jan Van de Winkel 22,299,220 1,862,790 12,570,123 David Kaufman 23,856,771 305,239 12,570,123”

HOOKIPA Pharma Inc.: Filed Certificate of Designation creating Series A-2 Convertible Preferred Stock (effective 2023-06-01).

“On June 1, 2023, the Company filed a Certificate of Designation of Series A-2 Convertible Preferred Stock with the Delaware Secretary of State”

HOOKIPA Pharma Inc. entered into Underwriting Agreement with SVB Securities LLC and RBC Capital Markets, LLC valued at $46.3 million (effective 2023-05-31).

“On May 31, 2023, HOOKIPA Pharma Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the underwriters listed on Schedule A thereto”

HOOKIPA Pharma Inc. reported First Quarter 2023 results: revenue $3.2 million, net income $19.7 million.

“Revenue was $3.2 million for the three months ended March 31, 2023 compared to $1.4 million for the three months ended March 31, 2022.”

Michael A. Kelly resigned as Director at HOOKIPA Pharma Inc..

“On April 7, 2023, Michael A. Kelly, a member of the Board, notified the Company of his resignation from the Board, including the Audit Committee of the Board (the “Audit Committee”), on which he serves as the Chair and a member and the Compensation Committee of the Board on which he serves as a member, effective April 7, 2023.”

HOOKIPA Pharma Inc. reported financial results for Fourth Quarter and Full Year 2022.

“On March 15, 2023, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2022.”

Terry Coelho was appointed as Director at HOOKIPA Pharma Inc..

“On March 9, 2023, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Terry Coelho as a director of the Board, effective April 3, 2023.”

HOOKIPA Pharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 17, 2023, HOOKIPA Pharma Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to be listed on the Nasdaq Global Se”

Malte Peters was appointed as Director at HOOKIPA Pharma Inc..

“On December 9, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Malte Peters, M.D. as a director of the Board, effective January 1, 2023.”

HOOKIPA Pharma Inc. reported Third Quarter 2022 results: revenue $2.2 million, net income $18.3 million.

“stock that Gilead is required to purchase at the discretion of the Company pursuant to the terms of a stock purchase agreement signed in February 2022 ​ Revenue: Revenue was $2.2 million for the three months ended September 30, 2022, compared to $3.9 million for the three months ended September 30, 2021. The decrease was primarily due to lower cost reimbursements”

Igor Matushansky was appointed as Chair of Scientific Advisory Committee at HOOKIPA Pharma Inc..

“Dr. Matushansky was also appointed to chair the Company’s newly formed Scientific Advisory Committee.”

Igor Matushansky resigned as Chief Medical Officer and Global Head of Research and Development at HOOKIPA Pharma Inc..

“On June 20, 2022, Igor Matushansky, M.D., Ph.D., who has served as the Chief Medical Officer and Global Head of Research and Development of the Company, notified the Company that he will resign from his current positions, effective as of June 30, 2022.”

Christine D. Baker was appointed as Chief Operating Officer at HOOKIPA Pharma Inc..

“On May 1, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Christine D. Baker as Chief Operating Officer, effective immediately.”

Timothy Reilly was appointed as Director at HOOKIPA Pharma Inc..

“On April 15, 2022, the Board appointed Timothy Reilly, Ph.D. as a director of the Board, effective immediately.”

Christoph Lengauer departed as Director at HOOKIPA Pharma Inc..

“On April 15, 2022, Christoph Lengauer, a member of the board of directors (the “Board”) of HOOKIPA Pharma Inc. (the “Company”), notified the Company that he will not stand for re-election to the Board when his term expires at the Company’s 2022 annual meeting of shareholders on June 30, 2022 (the “2022 Annual Meeting”).”